Click on headlines below to download research
Moderating costs to accelerate breakeven
Checkit | 15/09/2022
During H123 Checkit made further progress in its transition to a 100% subscription business, achieving 82% recurring revenue and a 48% y-o-y increase in…
ARR growth in a more cautious market
Checkit | 11/08/2022
Despite a challenging market environment, Checkit has grown annualised recurring revenue (ARR) by 48% y-o-y to £10.2m at the end of H123 and looks…
Growth strategy on track
Checkit | 28/04/2022
Checkit made good progress during FY22 with its strategy to transition to a pure SaaS business. Annualised recurring revenue (ARR) grew 44% y-o-y, helped…
FY22 ARR growth of 44%
Checkit | 17/02/2022
Checkit’s FY22 trading update confirmed it closed the year broadly in line with our revenue forecasts and, due to several contracts signed close…
Three-year contract with Biomat in the US
Checkit | 01/02/2022
Checkit has signed a three-year subscription contract with Biomat USA, a subsidiary of plasma and infusion medicines specialist Grifols, to provide its…